Gemina Laboratories Ltd. announced the signing of a license agreement with a significant global diagnostics company. The license agreement is the culmination of Gemina's commercialization program to date and will enable new licensing partner to develop, manufacture and sell new products using Gemina's IP platform. The agreement is significant for Gemina as it provides a compelling validation of its technology after extensive, detailed scrutiny and evaluation over the last year, by one of the most distinguished players in the $106 billion global in vitro diagnostics market1.

New partner considers its relationship with Gemina Labs as commercially confidential and has required Gemina to enter into certain confidentiality undertakings.